Non-vitamin K antagonist oral anticoagulants in adults with congenital heart disease

Table 2 Summary of the use of NOACs versus VKA in adult congenital heart disease

Author	Total patients, n	Age, years Mean ± SD	Severity of CHD, %			Indication for anticoagulation, %			Thromboem bolic events, % per year	Bleeding events, % per year
Author	Total patients, n	Age, years Mean ± SD	Simple	Moderate	Complex	AA	Primary TP	Secondary TP	Thromboem bolic events, % per year	Bleeding events, % per year
NOACs therapy
Pujol et al. [10]
NOACs	75	50 ± 13	45	34	21	76	0	24	0	0
Pujol et al. [12]
NOACs	215	48.4 ± 15.4	32.1	23.7	44.2	66.8	5.6	42.9	0.7	3.1
NOACs vs. VKA
Yang et al. [11]
NOACs	54	47.3 (38–61)	15	52	33	NA	NA	23	NA	NA
VKA	45	52.0 (37–61)	16	60	24	NA	NA	17	NA	NA
Yang et al. [13]
NOACs	530	47.0 ± 15.0	14.9	45.1	40.0	90.8	3.2	6.0	1.0	1.1
VKA	150	47.0 ± 16.0	14.6	38.6	46.6	NA	NA	NA	1.2	1.1
Freisnger et al. [14]
NOACs	1653	Median 70 (range 57–78)	68.3	24.2	7.5	72.7	NA	NA	2.8	11.7
VKA	4851	Median 69 (range 54–76)	63.8	23.1	12.9	63.2	NA	NA	3.7	6.7

AA, atrial arrhythmias; CHD, congenital heart disease; NOACs, non-vitamin K antagonist oral anticoagulants; TP, thromboprophylaxis; VKA, vitamin K antagonist

ISSN: 2466-1171